Does Rallies show 13F holders for INBS?

Yes. Rallies tracks hedge fund and 13F ownership data for INBS, including fund names, share counts, latest tracked quarter, and position changes when available.

Is INBS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for INBS. It does not provide personalized investment advice.

INBS (Intelligent Bio Solutions Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Intelligent Bio Solutions Inc. Common Stock (INBS) is a publicly traded Healthcare sector company. As of May 21, 2026, INBS trades at $2.90 with a market cap of $8.73M and a P/E ratio of 0.34. INBS moved -11.85% today. Year to date, INBS is -74.27%; over the trailing twelve months it is -77.89%. Its 52-week range spans $2.27 to $27.50. Rallies surfaces INBS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns INBS stock?

Hedge funds tracked by Rallies that own INBS include Two Sigma and Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Intelligent Bio Solutions Inc. Common Stock.

INBS Key Metrics

Key financial metrics for INBS
Metric	Value
Price	$2.90
Market Cap	$8.73M
P/E Ratio	0.34
EPS	$8.95
Dividend Yield	0.00%
52-Week High	$27.50
52-Week Low	$2.27
Volume	169.68K
Avg Volume	0
Revenue (TTM)	$3.91M
Net Income	$-11.65M
Gross Margin	47.25%

Top Hedge Funds Holding INBS

Two Sigma holds 15.40K shares of INBS, changed -47.70% as of Dec 31, 2024.
Citadel Advisors holds 14.84K shares of INBS, changed -90.51% as of Mar 31, 2024.

Latest INBS News

Q3 Revenue Up 46% to $1.06M as Margins Exceed 50% — May 13, 2026
Intelligent Bio Solutions Launches Study to Achieve Sub-3-Minute Drug Screening — Apr 20, 2026
Intelligent Bio Solutions Validates Security with Zero Vulnerabilities Ahead of FDA 510(k) Bid — Apr 17, 2026
Intelligent Bio Solutions Completes Codeine Detection Study in 40 Adults, Advances FDA 510(k) Program — Apr 2, 2026
Intelligent Bio Solutions Secures Eighth European Patent for Volume-Corrected Fingerprint Testing — Mar 26, 2026

Recent INBS Insider Trades

Simeonidis Harry bought 50 (~$92.5) on Sep 1, 2023.
Simeonidis Harry bought 100 (~$192) on Aug 31, 2023.

INBS Analyst Consensus

INBS analyst coverage data. Average price target: $0.00.

Common questions about INBS

Who owns INBS stock?: Hedge funds tracked by Rallies that own INBS include Two Sigma and Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Intelligent Bio Solutions Inc. Common Stock.
Does Rallies show 13F holders for INBS?: Yes. Rallies tracks hedge fund and 13F ownership data for INBS, including fund names, share counts, latest tracked quarter, and position changes when available.
Is INBS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for INBS. It does not provide personalized investment advice.